Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Valiant Laboratories Limited specializes in manufacturing pharmaceutical intermediates, particularly paracetamol API.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Valiant Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 08, 2024. Further, the company has informed the Exchange regarding voting results. | Download
Valiant Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 08, 2024. Further, the company has informed the Exchange regarding voting results. | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant